Myasthenia Gravis Pipeline Analysis 2018 - Focus on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Myasthenia Gravis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments” report has been added to ResearchAndMarkets.com’s offering.
This report covers 17 drugs currently in different phases of development.
The report provides Myasthenia Gravis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.
Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Key Topics Covered
1.1. Research Methodology
1.2. Research Scope
2. Disease Overview
3. Executive Summary
4. Market Dynamics
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by PhaseDrug Name Generic Name Synonyms Company Collaborator Route of Administration Target Mechanism of Action Technology Molecule Type CAS Number Weight Chemical Formula IUPAC Name ATC Code
5.3. By Molecule Type
5.4. Analysis by Region
6. Company Profiling
6.1. Akari Therapeutics
6.2. Alpha Cancer Technologies
6.3. Apellis Pharmaceuticals, Inc.
6.5. Bristol-Myers Squibb
6.6. Catalyst Pharmaceuticals
6.7. CSL Behring
6.10. Grifols Therapeutics LLC
6.11. GT Biopharma, Inc.
6.12. HanAll BioPharma Co., Ltd.
6.13. Neurotune AG
6.16. RA Pharmaceuticals
6.17. Toleranzia AB
6.18. UCB Pharma
For more information about this report visit https://www.researchandmarkets.com/research/kgww85/myasthenia_gravis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605005845/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs,Clinical Trials
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 06:31 AM/DISC: 06/05/2018 06:31 AM